|
LDA NEWS & UPDATES
September 30, 2023
| |
Virtual, Friday, October 13, 2023 & Saturday, October 14, 2023
New--Conference Recording: Available to view through Oct. 22, 2023 for those registrants who register by conference time.
STILL AVAILABLE: MEDICAL CATEGORY SCHOLARSHIPS
A few scholarships are still available for medical students, researchers, recent medical professionals, and health department representatives. Apply today!
| | |
|
Microorganisms (Horowitz, R., et al.) 9.12.23, published “Comparison of the Efficacy of Longer versus Shorter Pulsed High Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome with Bartonellosis and Associated Coinfections” in a special issue, Bartonella and Bartonellosis: New Advances and Further Challenges. The study of included twenty-five patients (15 men/10 women) diagnosed with relapsing and remitting Borreliosis, Babesiosis, and Bartonellosis, over periods of <5 to over 20 years. Read more. | |
The DailyMail.com (Luke Andrews) 9.26.23, has reported in an exclusive news article “Experimental Lyme disease pill laces your skin with poison – killing parasites before they infect.” Tarsus Pharmaceuticals, a California-based company has developed an experimental drug that will kill ticks that bite human skin. Read more. | |
|
Journal of the Pediatric Infectious Diseases Society (Thompson, A.D., et al) 9.26.23 published, “Sensitivity of Two-Tiered Lyme Disease Serology in Children with an Erythema Migrans Lesion.” Results of this study showed that sensitivity of serologic detection of Lyme disease was higher in children that presented with multiple erythema migrans (EM) lesions, than those with a single lesion. However, less than 77% of children that developed multiple lesions and less than 39% of children that developed a single lesion tested positive by two tier serology. Read more. | |
| |
|
British Pharmacological Society Journals (Clark, I.A. and Vissel, B.) 9.26.23, published “Autocrine positive feedback of tumor necrosis factor from activated microglia proposed to be of widespread relevance in chronic neurological disease.” The authors suggest persistence of tumor necrosis factor (TNF) through a “positive feedback loop” of this cytokine is | |
involved in chronic central nervous system (CNS) illnesses. The disease states are proposed to occur from excess TNF which creates persistent activation of microglial (brain/spinal) cells that are produced during this process. By delivering the specific anti-TNF biological, etanercept, to the central nervous system through perispinal administration, certain neurological conditions may be reversed. Read more. | |
The Journal of Clinical Microbiology (Drews, S.J.; et al.) 9.26.23 published, “Transfusion-transmitted Babesia spp.: a changing landscape of epidemiology, regulation, and risk mitigation.” In this mini review, authors describe the epidemiology of Babesia for humans, vectors, and pathogen hosts as impacts of climate change influence occurrence and risks associated with this pathogen. Read more. | |
| |
|
Courthouse News Service (Cameron Langford) 9.7.23, published an update on the 5th Circuit court case dealing with claims of patients against the Infectious Diseases Society of America (IDSA). In 2017, Lisa Torrey and 27 other people suffering from Lyme disease sued the IDSA, seven health insurance companies, and several medical doctors in a Texas federal court (RICO Act and antitrust claims). This case has undergone several appeals. Read more. | |
Mount Sinai website, 9.20.23, published the press release “Mount Sinai Receives $6.2 Million Grant from the Steven & Alexandra Cohen Foundation for the Clinical Care of Long Lyme Disease.” Mount Sinai’s Department of Rehabilitation and Human Performance received the grant from the Steven & Alexandra Cohen Foundation to expand the Cohen Center for Recovery From Complex Chronic Illnesses (CoRE). Read more. | |
| |
|
Children’s National Hospital – Congenital Infection Program has launched a pilot study being led by Sarah Mulkey, MD, PhD, “Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure.” This study is funded by the Clinical Trials Network for Lyme and Other Tick-borne Diseases which is supported by a grant from the Steven & Alexandra Cohen Foundation, the largest private funder of Lyme and tick-borne disease research in the country. Read more. | |
Valneva SE and Pfizer Inc. announced, in a press release featured on BioSpace, 9.7.23, data showing positive pediatric and adolescent immunogenicity and safety for, VLA15, their Lyme disease vaccine candidate, when administered as a booster. These results, taken from the Phase 2 study one month after the booster dose, showed a notable anamnestic antibody response in pediatric and adolescent participants as well as in adults. Read more. | |
|
Asian Longhorned Ticks; Courtesy, James Occi, PhD | |
Journal of Medical Entomology (Dye-Braumuller, K.C., et al.) 9.2.23 published “Invasive Haemaphysalis longicornis (Acari: Ixodidae) investigation in South Carolina: new records of establishment, pathogen prevalence, and blood meal analyses.” The study investigated the pathogen infection prevalence and blood meal preferences of Asian longhorned ticks following their discovery in a northern South Carolina county in June 2022. Read more. | |
Journal of Clinical Investigation (Kanjana, K., et al.) 7.20.23 “Autoimmunity to synovial extracellular matrix proteins in patients with postinfectious Lyme arthritis.” In this study, researchers utilized immunopeptidomics, a new technique to evaluate antigens in organisms, to detect HLA-DR–presented peptides from synovial tissues in a subgroup of patients presenting with post-infectious Lyme arthritis. Potential Borreliella burgdorferi–mimic (Bb-mimic) epitopes were also found. Read more. | |
| |
|
Advanced Science (Xu, J., et al.) 8.31.23 published “Developing a Blood Cell-Based Diagnostic Test for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Using Peripheral Blood Mononuclear Cells.” In this study, researchers utilized a single-cell Raman platform (noninvasive microspectroscopy) and artificial intelligence (AI) to analyze peripheral blood cells from patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and control subjects. Read more. | |
Parasites & Vectors (Arahirwa V., et al.) 8.24.23, published “Impact of the COVID-19 pandemic on delays in diagnosis and treatment of tick-borne diseases endemic to southeastern USA.” This article discusses how the COVID-19 pandemic affected the diagnosis and treatment of diseases transmitted by ticks, e.g., Lyme disease. Read more. | |
| |
|
JAMA (Raison, C.L., eta al.) 8.31.23 published “Single-Dose Psilocybin Treatment for Major Depressive Disorder - A Randomized Clinical Trial." In this study, researchers evaluated single dose psilocybin for its antidepressant effects and safety in patients with Major Depressive Disorder (MDD). Read more. | |
|
ATTENTION!
LEARN ABOUT STOPPING SPREAD OF TICKS & TBD!
IPM Institute Presents Tick Academy
October 11,12 10 AM - 2 PM Central Time
CEUs offered in CA, IN, OH, MI, MN, MT, NJ, and WA.
LDA is a Gold Sponsor of this event.
For more information and to register.
| |
|
The Lyme Disease Association Inc. (LDA) does not charge any membership fees. Most of our
materials are free to download and most of our videos are free on YouTube. Our nationwide
doctor referral system is free to access. Printed brochures can be ordered for the cost of S&H.
| |
888-366-6611 Toll Free Info Line
| | | | |
